All articles tagged with #replimune
The FDA rejected Replimune’s RP1 melanoma candidate for a second time, citing that the Ignyte trial data do not show substantial evidence of effectiveness and that new trial data are unpersuasive (only about 10% of planned patients treated and no prespecified progression-free survival data). The agency’s ruling leaves RP1’s future uncertain and prompted a roughly 20% drop in Replimune’s stock.
The FDA has once more rejected Replimune’s engineered virus therapy for advanced melanoma, a decision that underscores the ongoing debate over tightening agency standards amid leadership changes; the treatment is designed to boost the immune system’s attack on skin cancer, but regulators say the data remain insufficient.
San Diego's biotech industry is experiencing a downturn with job losses and increased lab vacancy rates, partly due to the FDA's rejection of Replimune's melanoma drug, which was influenced by FDA cancer chief Richard Pazdur's intervention, not Vinay Prasad.
The FDA's top cancer drug regulator, Richard Pazdur, played a key role in the rejection of Replimune's skin cancer therapy, RP1, amid internal agency dysfunction and leadership changes, despite support from other officials. The decision was influenced by internal debates and procedural issues within the FDA.
Replimune's stock plummeted 77.2% after the FDA unexpectedly rejected its experimental melanoma drug, citing insufficient data from midstage studies, which surprised investors and analysts who had anticipated approval based on positive preliminary results.
The FDA rejected Replimune's skin cancer therapy RP1 due to insufficient evidence of effectiveness and issues with clinical trial data, reflecting a tougher regulatory stance on new drug approvals.